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Abstract  1 
Background: The peroxisome proliferator activated receptors (PPARs) are transcriptional 2 
regulators of lipid metabolism, activated by unsaturated fatty acids. 3 
Objective: We investigated independent and interactive effects of PPARγ2 gene PPARG 4 
Pro12Ala (rs1801282) and PPARα gene PPARA Leu162Val (rs1800206) SNP genotypes 5 
with dietary intake of fatty acids on concentrations of plasma lipids in subjects at increased 6 
cardiometabolic risk. 7 
Design: The RISCK study is a parallel design, randomized controlled trial. Plasma lipids 8 
were quantified at baseline after a 4-wk high-SFA (HS) diet and after a 24-wk intervention 9 
with reference (HS), high-MUFA (HM) and low-fat (LF) diets. SNPs were genotyped in 466 10 
subjects.  11 
Results:  At baseline, carriage of the PPARG Ala12 allele was associated with increased 12 
plasma total cholesterol (n = 415; P = 0.05), LDL-cholesterol (P = 0.04) and apoB (P = 0.03)  13 
after adjustment for BMI, age, gender and ethnicity. PPARA Val162Leu x PPARG Pro12Ala 14 
genotype interaction influenced total cholesterol (P = 0.04) and triglyceride (P = 0.03) 15 
concentrations after adjustment for covariates. After HM and LF diets, total cholesterol, 16 
LDL-cholesterol and apoB concentrations were reduced (Ps < 0.001) and gene x gene 17 
interaction determined LDL-cholesterol (P = 0.02) and triglyceride (P = 0.002) 18 
concentrations after adjustments. After the HM diet, carriage of both variant alleles was 19 
associated with a greater reduction in LDL-cholesterol and increase in triglycerides 20 
compared to other genotype combinations. 21 
Conclusions: Interaction between PPARG Pro12Ala and PPARA Leu162Val genotypes is a 22 
significant determinant of plasma LDL-cholesterol and triglyceride concentrations after a 23 
high-MUFA diet.  24 
 25 
Keywords: Keywords: peroxisome proliferator activated receptor-γ (PPARγ), peroxisome 26 
proliferator activated receptor-α (PPARα), single nucleotide polymorphism, polyunsaturated 27 
fatty acid, saturated fatty acid, gene-nutrient interaction. 28 
INTRODUCTION  29 
The peroxisome proliferator activated receptors are master transcriptional regulators of lipid 30 
and carbohydrate metabolism (1). The major natural ligands of PPARγ are polyunsaturated 31 
fatty acids and prostanoids (2) and PPARα responds to several fatty acids (3), suggesting 32 
roles in transducing nutritional into metabolic signals (4). Once activated, PPARs 33 
heterodimerise with the retinoid X-receptor and bind to specific peroxisome proliferator 34 
response elements (PPREs) in the promoter regions of target genes. Activation of PPARγ2, 35 
expressed mainly in adipose tissue, stimulates adipogenesis by regulating a subset of genes 36 
involved in fatty acid transport and synthesis of triglycerides (5). PPARα plays an important 37 
role in liver, where it increases uptake of fatty acids and activates expression of genes 38 
involved in peroxisomal and mitochondrial β-oxidation (3). The PPARs are thus major 39 
regulators of lipid metabolism, capable of responding to nutritional status. 40 
Variants of the PPARγ2 gene PPARG and PPARα gene PPARA may alter the 41 
function of the receptors and their response to dietary agonists. Numerous studies have 42 
investigated associations of the single nucleotide polymorphisms (SNPs) Pro12Ala 43 
(rs1801282) in PPARG and Leu162Val (rs1800206) in PPARA with variables characterising 44 
the metabolic syndrome, although the results have been equivocal. In the original study by 45 
Deeb et al. (6), PPARG Ala12 carriers had a significantly lower BMI, but some later studies 46 
demonstrated a modest increase (7-10). Carriage of PPARA Val162 has been associated with 47 
components of the metabolic syndrome in some studies (11, 12) but not in others (13). 48 
Inconsistencies in the outcomes of SNP association studies suggest that environmental 49 
influences or gene-gene interaction may be influential. Compared to wild-type receptors, the 50 
PPARγ-Ala variant exhibits reduced binding to DNA and modest impairment of 51 
transcriptional activation by pharmacological ligands in vitro (6, 14) and the PPARα-Val 52 
form shows lower transcriptional activation in transfectants activated with ω-fatty acids (15). 53 
These findings raise the possibility that differential responses of PPAR gene variants to 54 
endogenous ligands might influence plasma variables controlled by target genes.  55 
We hypothesised that carriage of PPARG Pro12Ala and PPARA Leu162Val allelic 56 
combinations might influence concentration of plasma lipids according to availability of 57 
dietary unsaturated fatty acid ligands. We studied 466 men and women aged 30-70 y at 58 
increased risk of the metabolic syndrome in the RISCK study, a highly-controlled 59 
intervention based on replacement of saturated fat with either monounsaturated fat or 60 
carbohydrate in isoenergetic diets (16). Independent and interactive effects of PPARG 61 
Pro12Ala and PPARA Leu162Val genotypes in determination of plasma lipid concentrations 62 
were assessed at baseline after 4 wk run-in on the high saturated fat diet and after 24 wk of 63 
dietary intervention.  64 
 65 
SUBJECTS AND METHODS 66 
Subjects 67 
Ethical approval for the RISCK study (ISRCTN29111298) was granted from the National 68 
Research Ethics Service and written informed consent from participants was obtained, 69 
including subsequent genetic analyses. Men and women (age range: 30-70 y) recruited from 70 
the general population, attended a clinic in a fasting state at the participating centers 71 
(University of Reading, Imperial College London, University of Surrey and the Medical 72 
Research Council Human Nutrition Research Centre (MRC-HNR), University of Cambridge 73 
and Kings College London). 47.5% of the subjects had metabolic syndrome according to the 74 
criteria of the International Diabetes Federation (17).  549 subjects completed the RISCK 75 
study. The current study involved 466 subjects for whom DNA samples were available. Self-76 
reported ethnicity was recorded as White, South Asian, Black African, or other.  77 
 78 
Study design  79 
The RISCK study is a parallel 2 × 2 factorial design compared with a control intervention 80 
(16). The intervention diets were planned to provide similar intakes of dietary energy but to 81 
vary in the amount and type of fats and carbohydrates. All participants followed a 4-wk run-82 
in period during which they consumed a high-saturated fat ‘reference diet’ before being 83 
randomised to the reference diet or one of four isoenergetic dietary interventions designed to 84 
lower saturated fat. In this study, the dietary intervention groups differing in carbohydrate 85 
quality were combined to focus the analyses on the manipulation of dietary fat. The resulting 86 
three dietary groups were: high saturated fat ‘reference diet’ (HS) designed to reflect 87 
saturated fat intake in a ‘Western’ diet (~18% of energy SFA, 12% MUFA, 38% total fat, 88 
45% CHO), ‘high-MUFA diet’ (HM) in which SFA was reduced and replaced with MUFA 89 
(~10% of energy SFA, 20% MUFA, 38% total fat, 45% CHO) and ‘low-fat diet’ (LF), in 90 
which SFA was reduced through replacement of total fat with carbohydrate (~10 % of energy 91 
SFA, 11% MUFA, 28% total fat, 55% CHO). The dietary intervention is described in detail 92 
elsewhere (18). Measurements made after the run-in diet are referred to as ‘baseline’. All 93 
participants followed their randomly prescribed diets for 24 wk, after which a further blood 94 
sample was collected and anthropometry measured. Unweighed 4-d food diaries (3 weekdays 95 
and 1 weekend day) were collected to record dietary intakes at baseline and in the third and 96 
the final month of the intervention. Nutrient intakes were estimated by using the food-97 
composition database software DINO as described previously (16). Weight (in light clothing) 98 
and height (without shoes) were measured and an indwelling venous cannula was inserted 99 
into the forearm.  100 
 101 
Blood analytic methods 102 
Blood samples for analysis were drawn after a minimum 8-h overnight fast and serum was 103 
stored at -45 °C until analyzed. Fasting lipids including total cholesterol and triglycerides 104 
were measured as described previously (16).  LDL-cholesterol was derived from the 105 
Friedwald equation.  Fasted plasma phospholipid fatty acids were measured by GC at the 106 
University of Reading as described previously (18).  107 
 108 
DNA extraction and SNP genotyping 109 
Buffy coats removed from blood samples were stored in EDTA at -20°C. Genomic DNA was 110 
extracted from 200 µl buffy coat using an Illustra blood genomic prep mini spin kit (GE 111 
Healthcare, Amersham, UK) according to manufacturer’s instructions. Genotyping by was 112 
performed in the 466 participants for whom DNA was available. The PPARG Pro12Ala SNP 113 
(rs1801282) was genotyped by KBiosciences (Hoddesdon, UK). Genotype accuracy as 114 
assessed by inclusion of duplicates in the array was 98% and negative controls (water blanks) 115 
were included on each plate. Genotyping success rate was 89%. PPARA Leu162Val (rs 116 
rs1800206) was genotyped by Pyrosequencing (Qiagen, Crawley, UK).  Template PCR 117 
amplifications were 1 cycle at 94 °C for 6 min; 50 cycles at 94 °C for 1 min, 60 °C for 45 s 118 
and 72 °C for 1 min; 1 cycle at 72°C for 10 min in a buffer containing 1X RedTaq 119 
polymerase buffer, 2.5 mM MgCl2, 0.4 µM dNTP, 200 µM primers and 0.2 U RedTaq 120 
polymerase.  Template primers were as follows: Forward: 5’-121 
GCCAGTATTGTCGATTTCACAAGT-3’; reverse 5’-bio-122 
TTACCTACCGTTGTGTGACATCC-3’. The forward sequencing primer was: 5’-123 
TCGATTTCACAAGTGC-3’. All reagents and primers were from Sigma-Aldrich, 124 
(Gillingham, Dorset, UK).  Genotyping accuracy was 98% and success rate was 97%. 125 
 126 
Statistical analyses  127 
All genotype distributions were tested for deviation from the Hardy-Weinberg equilibrium by 128 
a χ2 test with 1 df (P > 0.05). Statistical analyses were carried out using the SPSS version 129 
17.0 for Windows (SPSS Inc, Chicago, IL, USA).  Data were analyzed by using analysis of 130 
covariance (ANCOVA), regressing follow-up measures against baseline measures with 131 
ethnicity, baseline age, gender and diet as covariates. Outliers were excluded from the 132 
ANCOVA and were defined as points > 2.5 times the interquartile range from the median on 133 
the transformed scale at baseline, follow-up, or change from baseline. All data presented in 134 
text and tables are expressed as means ± SD or 95% CI. The effect of each diet is expressed 135 
as the follow-up values above the baseline with 95% CI. Statistical significance was taken at 136 
P < 0.05. 137 
 138 
RESULTS 139 
Baseline characteristics of subjects 140 
The characteristics of the 466 participants in this study after the baseline reference (HS) diet 141 
are presented in Table 1.  There were significant differences between males and females (P < 142 
0.001) in a number of variables as shown. 143 
 144 
SNP allele and genotype frequencies 145 
Online supplementary Table 1 shows the allele and genotype frequencies for PPARG 146 
Pro12Ala and PPARA Leu162Val in the 466 RISCK subjects. Genotype distributions did not 147 
deviate from Hardy-Weinberg expectations. In comparison to MAFs listed on the NCBI SNP 148 
database (build 132 accessed 01/01/11) (http://www.ncbi.nlm.nih.gov/snp), the PPARG 149 
Ala12 allele was more frequent in RISCK Whites than HapMap Europeans (0.076 in 150 
HapMap-CEU) and absent in Blacks, as in HapMap-YRI (Sub-Saharan African). The 151 
PPARA Val162 allele was also more frequent in RISCK Whites (0.042 in HapMap-CEU) 152 
and absent in Blacks, as in HapMap-YRI trios. There is no comparative data available for the 153 
S. Asian subjects.  154 
 155 
Independent associations of genotypes with concentrations of plasma lipids at baseline 156 
Diet during the 4 wk run-in to baseline on the HS reference diet was monitored by weighed 157 
intake (18). Table 2 shows plasma lipid measurements at baseline, stratified by PPARG 158 
Pro12Ala and PPARA Leu162Val genotypes. Carriers of the PPARG Ala12 allele had 5.4% 159 
higher total cholesterol, 5.7% higher LDL-cholesterol and 11% higher apo B than Pro12 160 
homozygotes, differences which were significant after adjustment for BMI, age, gender and 161 
ethnicity. There were no significant associations of PPARA Leu162Val genotype with 162 
plasma lipid concentrations.  163 
 164 
Effect of interaction between genotypes on concentrations of plasma lipids at baseline 165 
Subjects for whom PPARG Pro12Ala and PPARA Leu162Val genotype data was available  166 
(n = 401) were divided into four genotype groups defined by presence or absence of the 167 
variant alleles. Mean concentrations of plasma lipids with respect to genotype combinations 168 
are shown in Table 3. There was a significant interaction between genotypes as determinants 169 
of total cholesterol and triglyceride concentrations after adjustment of all data and P-values 170 
for BMI, gender, age and ethnicity. Carriage of PPARA Val162 was associated with higher 171 
plasma total cholesterol and triglyceride concentrations in PPARG Ala12 carriers than in 172 
Pro12 homozygotes at baseline.  173 
 174 
Change in concentrations of plasma lipids after dietary intervention 175 
Subjects were randomly assigned to continuation on the HS reference diet, or 24 wk on an 176 
isoenergetic diet, in which saturated fat was replaced with either MUFA (HM diet) or 177 
carbohydrate (LF diet). There was no significant difference in intake of saturated fat during 178 
the run-in between groups randomised to the interventions. Body weight was relatively 179 
stable. Further information is provided elsewhere (16, 18). The changes in % SF and % 180 
MUFA differed between the diets over the 24 wk of intervention. The HM group had 181 
significantly lower plasma phospholipid % SF than the LF group and higher % MUFA, but 182 
other fatty acid classes [(n-3) PUFA, (n-6) PUFA and trans FA] were not affected (18). 183 
Total- and LDL-cholesterol concentrations were significantly lower after consumption of 184 
HM and LF than after the HS reference diet. ApoB concentrations differed between treatment 185 
groups and were lower after the HM and LF diets than the HS diet. There were no significant 186 
changes in plasma triglyceride concentrations (16).  187 
 188 
Effect of interaction between genotypes on concentrations of plasma lipids after dietary 189 
intervention 190 
Independent associations of PPARG Pro12Ala or PPARA Leu162Val genotypes with 191 
changes in concentrations of plasma lipids with respect to baseline were not significant after 192 
randomisation to continued HS reference, or switch to HM and LF diets (data not shown).  193 
Investigation of genotype interaction was based on subjects genotyped for both SNPs, with 194 
measurements of plasma lipids after HM (n = 227) and LF (n = 236) diets. There was a 195 
significant interaction between PPARG Pro12Ala and PPARA Leu162Val genotypes as 196 
determinants of plasma LDL-cholesterol, (P = 0.02) and triglyceride (P = 0.002) 197 
concentrations after adjustment for change in BMI, age, gender and ethnicity. After the HM 198 
diet, carriage of the Val162 allele caused an 8-fold greater reduction in plasma LDL-199 
cholesterol in Ala12 carriers than in Pro12 homozygotes. In the absence of the Val162 allele, 200 
reduction in plasma LDL-cholesterol in Ala12 carriers was less than in Pro12 homozygotes. 201 
After the LF diet, presence or absence of the Val12 allele had no effect on plasma LDL 202 
cholesterol concentration. Carriage of the PPARA Val162 allele caused a 15-fold greater 203 
increase in plasma triglycerides in PPARG Ala12 carriers than in Pro12 homozygotes. In the 204 
absence of the Val162 allele, plasma triglycerides only varied by 10% between Ala12 205 
carriers and Pro12 homozygotes. After the LF diet, plasma triglyceride concentration 206 
dependent on presence or absence of the Val162 allele varied by 20%.  207 
Figure 1 shows the follow-up concentrations of plasma LDL-cholesterol and 208 
triglycerides after the HM and LF diets above the baseline, with respect to PPARG Pro12Ala 209 
and PPARA Leu162Val genotype combinations. Data on which Figure 1 is based are 210 
available in Online Supplementary Material Table 2.  The differences in plasma lipid 211 
concentrations between co-carriers of PPARG Ala12 and PPARA Val162 and all other 212 
genotype combinations were significant (P < 0.01). We also included triglyceride as a 213 
covariate in the LDL-cholesterol model to see if the relationship between these variables 214 
might explain the similarity of the same small genotype group exhibiting differences. 215 
However, the covariate was not significant, suggesting that the effects are independent of one 216 
another.  217 
 218 
DISCUSSION   219 
We have shown independent and interactive effects of PPARγ2 gene PPARG Pro12Ala and 220 
PPARα gene PPARA Leu162Val genotypes in determination of plasma lipid concentrations, 221 
after diets lowering intake of SFA by replacement with MUFA or carbohydrate.  222 
The deleterious effects of dietary SFA on circulating lipids and lipoproteins are well 223 
known (19). When MUFA isocalorically replace SFA in the diet, plasma LDL-cholesterol 224 
decreases and HDL-cholesterol concentration is maintained. High MUFA diets cause 225 
significant reductions in triglycerides compared to high carbohydrate (low fat) diets (20, 21). 226 
In RISCK participants, as expected, plasma total- and LDL-cholesterol and ApoB 227 
concentrations were significantly lower after consumption of HM and LF than after the HS 228 
reference diet. However, unexpectedly, there were no significant reductions in plasma 229 
triglyceride concentrations (16). 230 
After the 4-wk run-in on HS diet, carriers of the PPARG Ala12 allele had 231 
significantly higher plasma total cholesterol, LDL-cholesterol and apoB concentrations than 232 
Pro12 homozygotes. Although SFAs are relatively poor stimulators of PPARγ activity (22) 233 
the difference between genotypes is likely to reflect lower activation of target genes by the 234 
PPARγ-Ala form (6). The PPARA Leu162Val genotype was not associated with plasma 235 
lipids at baseline. Others have reported similarly (13, 23, 24, 25), but associations of Val162 236 
with higher (11, 26) and lower (27) concentrations of plasma triglycerides have previously 237 
been found. Co-carriage of PPARA Val162 was associated with higher concentrations of 238 
plasma total cholesterol and triglycerides in PPARG Ala12 carriers than in Pro12 239 
homozygotes at baseline. One other investigation found no significant interaction between 240 
these SNPs in determination of plasma lipid concentrations (28). 241 
Increased expression of PPARγ mRNA in adipose tissue (29) and PPARα mRNA and 242 
target genes in liver (30) after a high-fat diet in mice suggests that fat intake might influence 243 
target gene expression in humans. Neither PPARG Pro12Ala nor PPARA Leu162Val 244 
genotypes were independently associated with changes in concentrations of plasma lipids 245 
after intervention, although after randomisation, the power to detect significant changes was 246 
reduced. Various dietary interactions with Pro12Ala and Leu162Val have been reported. An 247 
initial study found total fat intake to be inversely correlated with total plasma cholesterol in 248 
PPARG Pro12 homozygotes, but MUFA intake was inversely associated with BMI in Ala12 249 
allele carriers (31), i.e. the responsiveness of Ala12 carriers depended on the type of fat. 250 
Luan et al. (32) previously found greater sensitivity of Ala12 allele carriers to dietary PUFA 251 
in determination of BMI. Both findings are compatible with unsaturated fatty acids acting as 252 
specific ligands for PPARγ (22) and lower transcriptional activity of the PPARγ-Ala variant 253 
(6) reducing adipogenesis. Reports of effects of PPARA Leu162Val interaction with fatty 254 
acid intake on plasma lipids are inconsistent, including no interaction with PUFA (33), 255 
association of Val162 with higher total- and LDL-cholesterol after a high-PUFA diet (34) 256 
and higher triglyceride after low PUFA intake (33).  257 
Our study is the first to report significant interaction between PPARG Pro12Ala and 258 
PPARA Leu162Val genotypes as a determinant of plasma lipid concentrations. After the HM 259 
diet there was a significantly larger reduction in plasma LDL-cholesterol and a significantly 260 
larger increase in triglyceride concentration in co-carriers of PPARG Ala12 and PPARA 261 
Val162 alleles than in any other genotype group. There were no such effects after the LF diet. 262 
PUFA is a stronger activator of PPARs than MUFA (22), but was constant in both 263 
interventions. As PPAR variant carriage affected plasma lipids only after the HM diet, the 264 
effects may depend on high MUFA concentration. 265 
Evidence for influence of PPARγ and PPARα on plasma lipoprotein concentrations 266 
has mainly come from studies of pharmacological ligands in vitro and in vivo. Reported 267 
effects of PPARγ agonist thiazolidinediones are mainly increased HDL-cholesterol, increased 268 
size/decreased density of LDL-cholesterol particles and increased lipoprotein (a) (35). 269 
Reported effects of PPARα agonist fibrates generally relate to reduced plasma triglycerides 270 
and an increase in HDL-cholesterol levels (36). However, there is evidence for potential 271 
influence of PPARγ and PPARα on LDL-cholesterol concentration. The insulin-induced gene 272 
INSIG1, a key regulator of SREBP activity, is up-regulated by activation of PPARγ in rat 273 
adipose tissue by rosiglitazone (37) and of PPARα in rat liver by clofibrate (38). PPARγ 274 
activation by troglitazone reduces nuclear SREBP-2 and down-regulates LDL clearance from 275 
plasma by SREBP-2 target, the liver LDL receptor (39). Expression of the LDL receptor is 276 
also reduced by clofibrate (33). Activation of PPARα and PPARγ would thus impair LDLR 277 
expression, down-regulate LDL clearance from plasma and increase circulating LDL-278 
cholesterol concentration. Ovalle and Bell (40) found that troglitazone and rosiglitazone 279 
increased plasma LDL-cholesterol concentrations in humans, but LDL apoB-100 levels 280 
generally decrease in response to fibrates (36). PPARγ-Ala12 and PPARα-Val162 forms 281 
have lower transactivational ability than the wild-types (6,15). Carriers of PPARG Ala12 and 282 
PPARA Val162 would express higher LDLR activity leading to maximum clearance and the 283 
largest fall in LDL-cholesterol concentration, as observed. All the other genotype 284 
combinations showed smaller reductions in LDL-cholesterol after the HM diet. As Ala12 285 
was associated with higher total cholesterol concentration and interaction with Val162 286 
yielded higher LDL-cholesterol after the HS diet, the lower LDL-cholesterol in carriers of 287 
both variants after the HM diet appears to be a response to increased availability of MUFA.  288 
Goldberg et al. (35) found troglitazone and pioglitazone lowered triglyceride levels, 289 
by a mechanism that may involve enhancement of triglyceride clearance, reduction of hepatic 290 
lipase and increase in ATP binding cassette A1 (ABCA1) activity. Another mechanism may 291 
involve inhibition of hepatic very low-density lipoprotein (VLDL) secretion. In general, 292 
fibrates act to reduce VLDL apoB-100 through enhanced clearance and reduced production 293 
(36). Reduced production of VLDL is also associated with n-3 PUFA consumption (41). 294 
Lipoprotein lipase (LPL) is a rate-limiting determinant of triglyceride hydrolysis and as the 295 
LPL gene is a target of both PPARγ (42) and PPARα (15) the triglyceride-lowering effect of 296 
both receptors could be mediated by this route. Rudkowska et al. (15) showed that after n-3 297 
PUFA dietary supplementation, LPL activity increased more in PPARA Leu162 298 
homozygotes than in Val162 carriers and enzyme activities were inversely related to plasma 299 
triglyceride concentration. Transcription after n-3 fatty acid transactivation was also found to 300 
be higher in Leu162- than Val162-constructs containing the LPL PPRE (43). These findings 301 
are compatible with the increased triglyceride concentration that we found in carriers of the 302 
less transcriptionally active Val162 allele after the HM diet. Co-carriage of the less active 303 
PPARG Ala12 allele could maximise the effect.  One other study has examined PPARG 304 
Pro12Ala and PPARA Leu162Val interaction after dietary intervention: a 2.5 y low energy 305 
diet in obese women, in whom there were significant favourable changes in lipid profile, but 306 
no significant interactive effects at baseline or at the follow-up (44).  307 
The strength of our study lies in its design as a randomized, tightly controlled feeding 308 
trial with high adherence and retention rates and diets with practical relevance to the general 309 
population. Limitations include reduced power after randomisation to dietary treatments, 310 
compared to that at baseline. However, the results of gene-gene interaction were highly 311 
significant for this data. Our ANOVA model used the variability of the whole dataset to 312 
measure the background variation, which was able to produce significant results even though 313 
the number of subjects was small. The results for LDL-cholesterol and triglycerides seem to 314 
be independent, which further strengthens both results and conclusion. The significance 315 
should nevertheless be treated with caution and confirmation awaits replication in a larger 316 
sample.  317 
 318 
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TABLE 1 
Characteristics of RISCK study subjects at baseline  
Characteristic 
All 
(n = 466) 
M 
(n = 191) 
F 
(n = 275) 
P 
M vs F 
                                            
Ethnicity1 
    
                                                  
South Asian [n (%)] 
                  
44 (9.4) 
                   
19 (9.9) 
                 
25 (9.1) 
 
                                           
Black African [n (%)] 
                      
38 (8.2) 
                          
10 (5.2) 
                      
28 (10.2) 
 
                                                         
White European [n (%)] 
                       
367 (78.8) 
                       
155 (81.2) 
                       
212 (77.1) 
 
                                                             
Others  
                 
17 (3.6) 
                   
7 (3.7) 
                  
10 (3.6) 
 
                                                    
Age (y) 52.4±9.9 53.5±10.3 51.6±9.5 
                    
0.04 
                                                    
BMI (kg/m2) 28.7±4.7 28.6±3.9 28.8±5.2 
                     
0.56 
Triglycerides (mmol/L) 1.5±0.7 1.7±0.8 1.4±0.6 
                 
<0.001 
Total cholesterol (mmol/L) 5.6±1.0 5.6±1.0 5.6±1.0 
                    
0.57 
                                                      
HDL cholesterol (mmol/L) 1.4±0.3 1.3±0.3 1.5±0.3 
                 
<0.001 
ApoA1 (g/L) 1.2±0.3 1.2±0.2 1.3±0.2 
                   
0.002 
LDL cholesterol (mmol/L) 3.5±0.8 3.6±0.8 3.5± 0.8 
                    
0.14 
ApoB (g/L) 0.97±0.3 1.00±0.3 0.96±0.3 
                     
0.09 
Data is presented for all subjects who completed the study and for whom DNA was available 
(n = 466). Values presented as mean ± SD. All variables were measured at baseline after 4-
wk run-in on reference HS diet. Significance of differences between males and females was 
determined by students t-test. 1Self-reported ethnicity.  
 
 
 
TABLE 2 
Independent associations of PPARG Pro12Ala and PPARA Leu162Val genotypes with phenotypes at baseline  
 PPARG Pro12Ala genotype   PPARA Leu162Val genotype  
Phenotype PP PA + AA P  LL LV + VV P 
Males n (%) 132 (77%) 40 (23%)   165 (41) 22 (43)  
Females n (%) 210 (86%) 33 (14%)   237 (59) 29 (57)  
BMI (kg/m2)1 28.8 (28.3,29.3) 27.9 (26.9,29.0) 0.141  28.7 (28.2,29.1) 29.5 (28.2,30.8) 0.17 
Total cholesterol (mmol/L) 5.5 (5.4,5.6) 5.8 (5.6,6.0) 0.03  5.6 (5.5,5.7) 5.5 (5.3,5.8) 0.15 
Triglycerides (mmol/L) 1.5 (1.4,1.5) 1.6 (1.5,1.8) 0.14  1.5 (1.4,1.6) 1.4 (1.2,1.6) 0.26 
HDL cholesterol (mmol/L) 1.4 (1.3,1.4) 1.4 (1.3,1.4) 0.88  1.4 (1.3,1.4) 1.4 (1.3,1.5) 0.97 
ApoA1 (g/L) 1.2 (1.2,1.2) 1.2 (1.2,1.3) 0.55  1.2 (1.2,1.2) 1.2 (1.2,1.3) 0.58 
LDL Cholesterol (mmol/L) 3.5 (3.4,3.6) 3.7 (3.5,3.9) 0.04  3.6 (3.5,3.6) 3.5 (3.3,3.7) 0.22 
ApoB (g/L) 0.9 (0.9,1.0) 1.0 (1.0,1.1) 0.03  1.0 (0.9,1.0) 1.0 (0.9,1.0) 0.53 
Data is presented for subjects for whom DNA samples were available (n = 466). All variables were measured at baseline after 4-wk run-in on 
reference HS diet. Values are mean (95% CI). P-values for analysis of variance based on a dominant model are shown, adjusted for age, gender, 
BMI and ethnicity nominally significant (P < 0.05) and remained significant after adjustment for multiple comparisons by 2-way ANOVA are 
shown in bold. 1P-value BMI adjusted for gender, age and ethnicity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3 
Effect of interaction of PPARA Leu162Val and PPARG Pro12Ala on plasma lipids at baseline  
 PPARA Leu162Val / PPARG Pro12Ala  genotype 
 
P 
Phenotype 
LL/PP                              
(n = 293) 
LL/PA+AA               
(n = 64) 
LV+VV/PP                                  
(n = 36) 
LV+VV/PA+AA             
(n = 8)   
PPARG 
P12A 
PPARA 
L162V Interaction 
Total cholesterol 
(mmol/L)     5.5 (5.4,5.6) 5.7 (5.5,6.0) 
                       
5.2 (4.9,5.5) 5.8 (5.1,6.5) 
 
                
0.03 
                
0.08 
                   
0.04 
Triglycerides 
(mmol/L) 1.5 (1.4,1.6) 1.6 (1.4,1.7) 
                       
1.2 (1.0,1.4) 1.9 (1.4,2.4) 
 
                   
0.13 
                
0.08 
                
0.03 
LDL cholesterol 
(mmol/L) 3.5 (3.4,3.4) 3.7 (3.5,3.5) 3.3 (3.0,3.0) 3.7 (3.1,3.1)  
                   
0.05 0.17 
                 
0.12 
ApoB 
(g/L) 0.96 (0.92,0.99) 1.02 (0.95,1.09) 0.87 (0.78,0.97) 1.07 (0.85, 1.29)  
                 
0.05 0.18 
                
0.08 
HDL-cholesterol 
(mmol/L) 1.4 (1.3,1.4) 1.4 (1.3,1.4) 1.4 (1.3,1.5) 1.3 (1.1,1.5)  0.91 0.99 
               
0.91 
ApoA1                                                                                                                                          
(g/L) 1.2 (1.2,1.2) 1.2 (1.2,1.3) 1.2 (1.1,1.3) 1.4 (1.2,1.5) 0.59 0.62 0.46 
Data is presented for subjects for whom PPARG Pro12Ala and PPARA Leu162Val genotype data was available (n = 401).  All variables were 
measured at baseline after 4-wk run-in on reference HS diet. Values are mean (95% CI). All data and P-values for analysis of variance are 
shown, adjusted for age, gender, BMI and ethnicity based on subjects. P-values nominally significant (< 0.05) and remained significant after 
adjustment for multiple comparisons by 2-way ANOVA are shown in bold.  
 
 
 
 
 
Figure legend  
Interaction between PPARG Pro12Ala and PPARA Leu162Val genotype groups after dietary 
treatments influences plasma lipid concentrations. Interaction between PPARG Pro12Ala and 
PPARA Leu162Val genotypes was a significant determinant of change in plasma 
concentrations of (A) LDL- cholesterol (P = 0.02) and (B) triglycerides (P = 0.002) after HM 
and LF diets, after adjustment for BMI, age, gender and ethnicity and corrected for multiple 
comparisons using 3-way ANOVA. PP represents subjects homozygous for the PPARG 
Pro12 allele and PA + AA carriers of the Ala12 allele. LL represents subjects homozygous 
for the PPARA Leu162 allele and LV + VV carriers of the Val162 allele. Mean follow-up 
concentrations of LDL-cholesterol and triglycerides (mmol/L) above the baseline, after 24 
wk on HM or LF diets are shown. Bars indicate 95% CI. The figure is based on subjects with 
genotypes for both SNPs and measurements of plasma lipids after HM and LF diets.  
 
 
 
 
 
 
 
 
 
 
 
